Genotypic distribution of HHV-8 in AIDS individuals without and with Kaposi sarcoma Is genotype B associated with better prognosis of AIDS-KS?

Imagem de Miniatura
Arquivos
art_TOZETTO-MENDOZA_Genotypic_distribution_of_HHV8_in_AIDS_individuals_without_2016.PDF (512.27 KB)
Citações na Scopus
18
Tipo de produção
article
Data de publicação
2016
DOI
Scopus
Web of Science
PubMed
Título da Revista
ISSN da Revista
Título do Volume
Editora
LIPPINCOTT WILLIAMS & WILKINS
Autores
TOZETTO-MENDOZA, Tania Regina
DREXLER, Jan Felix
Citação
MEDICINE, v.95, n.48, article ID e5291, 8p, 2016
Projetos de Pesquisa
Unidades Organizacionais
Fascículo
Resumo
AIDS-associated Kaposi's sarcoma (AIDS-KS) caused by human herpes virus 8 (HHV-8) is the most severe and resistant form of KS tumor. Our aim was to verify whether there is an association between HHV-8 variability and development of AIDS-KS in Brazil by comparing the HHV-8 variability between individuals without and with KS. Saliva samples and blood, when available, were analyzed by PCR techniques for detection of the fragments of ORF K1 of HHV-8, which were then genotyped and analyzed regarding the genetic variability. Our study described 106 positive cases for HHV-8 in the saliva from 751 AIDS patients without previous KS. In addition, we performed a phylogenetic analysis of HHV-8 in 34 of the 106 AIDS patients without KS and in 33 of the 37 patients with active KS. The distribution of HHV-8 genotypes A, B, C, and F in AIDS individuals was indistinguishable by comparing non-KS and KS groups, as well as regarding ethnicity. Considering the KS group, genotype B was associated with better prognosis of KS tumor. Interestingly. we found a particular profile of diversity within Glade C and 2 recombinant patterns of HHV-8 in the saliva of AIDS individuals without KS. We emphasize the need to achieve standard genotyping protocol for ORF K1 amplification, thus allowing for substantial detection of HHV-8 variants. Our findings can shed light on the role of HHV-8 variability in the pathogenesis of AIDS-KS.
Palavras-chave
AIDS-KS, genotype, HHV-8, ORF K1, saliva
URI
https://observatorio.fm.usp.br/handle/OPI/18153
Referências
  1. Berger SA, 2011, BIOINFORMATICS, V27, P2068, DOI 10.1093/bioinformatics/btr320
  2. Beyari MM, 2003, J INFECT DIS, V188, P678, DOI 10.1086/377504
  3. Biggar RJ, 2000, J INFECT DIS, V181, P1562, DOI 10.1086/315456
  4. Boralevi F, 1998, J INFECT DIS, V178, P1546, DOI 10.1086/314471
  5. Borges JD, 2012, J INFECT DIS, V205, P1869, DOI 10.1093/infdis/jis278
  6. Caterino-de-Araujo A, 1998, J INFECT DIS, V177, P1136
  7. CHANG Y, 1994, SCIENCE, V266, P1865, DOI 10.1126/science.7997879
  8. Cordiali-Fei P, 2015, J EXP CLIN CANC RES, V34, DOI 10.1186/s13046-014-0119-0
  9. da Silva SR, 2011, CANCER LETT, V301, P85, DOI 10.1016/j.canlet.2010.10.011
  10. de Souza VAUF, 2007, J INFECT DIS, V196, P844, DOI 10.1086/520549
  11. Duprez R, 2006, VIROLOGY, V353, P121, DOI 10.1016/j.virol.2006.04.026
  12. Edgar RC, 2004, NUCLEIC ACIDS RES, V32, P1792, DOI 10.1093/nar/gkh340
  13. Fouchard N, 2000, INT J CANCER, V85, P166, DOI 10.1002/(SICI)1097-0215(20000115)85:2<166::AID-IJC3>3.0.CO;2-L
  14. Ishak MDG, 2007, J MED VIROL, V79, P1537, DOI 10.1002/jmv.20995
  15. Hayward GS, 2007, CURR TOP MICROBIOL, V312, P1
  16. Isaacs T, 2016, J MED VIROL, V88, P292, DOI 10.1002/jmv.24328
  17. Kadyrova E, 2003, J MED VIROL, V71, P548, DOI 10.1002/jmv.10530
  18. Kajumbula H, 2006, INTERVIROLOGY, V49, P133, DOI 10.1159/000089374
  19. Kasolo FC, 2007, J MED VIROL, V79, P1555, DOI 10.1002/jmv.20952
  20. Kasolo FC, 1998, J GEN VIROL, V79, P3055
  21. Katoh K, 2002, NUCLEIC ACIDS RES, V30, P3059, DOI 10.1093/nar/gkf436
  22. Kouri V, 2005, AIDS, V19, P984, DOI 10.1097/01.aids.0000171416.07034.d6
  23. Kouri V, 2012, VIROLOGY, V432, P361, DOI 10.1016/j.virol.2012.06.014
  24. KRIGEL RL, 1983, CANCER TREAT REP, V67, P531
  25. Krishnan HH, 2004, J VIROL, V78, P3601, DOI 10.1128/JVI.78.7.3601-3620.2004
  26. KROWN SE, 1989, J CLIN ONCOL, V7, P1201
  27. Krown SE, 2008, NEW ENGL J MED, V358, P535, DOI 10.1056/NEJMc072994
  28. Lacoste V, 2000, VIROLOGY, V278, P60, DOI 10.1006/viro.2000.0629
  29. Leao JC, 2013, J MED VIROL, V85, P636, DOI 10.1002/jmv.23491
  30. Lennette ET, 1996, LANCET, V348, P858, DOI 10.1016/S0140-6736(96)03240-0
  31. Mancuso R, 2008, J MED VIROL, V80, P2153, DOI 10.1002/jmv.21322
  32. Mancuso R, 2011, J GEN VIROL, V92, P744, DOI 10.1099/vir.0.027847-0
  33. Marshall V, 2010, J INFECT DIS, V202, P1126, DOI 10.1086/656045
  34. Maurer T, 2007, NEW ENGL J MED, V357, P1352, DOI 10.1056/NEJMc070508
  35. Nascimento MC, 2005, J CLIN VIROL, V33, P52, DOI 10.1016/j.jcv.2004.09.026
  36. Otvos R, 2014, ANTICANCER RES, V34, P893
  37. Olp LN, 2015, J VIROL, V89, P12299, DOI 10.1128/JVI.01712-15
  38. Pierrotti LC, 2000, J CLIN VIROL, V16, P247
  39. Poole LJ, 1999, J VIROL, V73, P6646
  40. SAIKI RK, 1985, SCIENCE, V230, P1350, DOI 10.1126/science.2999980
  41. Stamatakis A, 2005, BIOINFORMATICS, V21, P456, DOI 10.1093/bioinformatics/bti191
  42. Stebbing J, 2003, J VIROL, V77, P4306, DOI 10.1128/JVI.77.7.4306-4314.2003
  43. Stebbing J, 2008, AIDS, V22, P551, DOI 10.1097/QAD.0b013e3282f4de5d
  44. Strathdee S A, 1996, AIDS, V10 Suppl A, pS51, DOI 10.1097/00002030-199601001-00008
  45. Tomlinson CC, 2004, J VIROL, V78, P1918, DOI 10.1128/JVI.78.4.1918-1927.2004
  46. Tornesello ML, 2010, VIROLOGY, V398, P280, DOI 10.1016/j.virol.2009.12.005
  47. Whitby D, 2004, J GEN VIROL, V85, P155, DOI 10.1099/vir.0.19465-0
  48. Yao SH, 2015, NUCLEIC ACIDS RES, V43, P9362, DOI 10.1093/nar/gkv988
  49. Zhang ZG, 2016, J VIROL, V90, P7657, DOI 10.1128/JVI.03102-15
  50. Zong JC, 2002, J CLIN VIROL, V23, P119, DOI 10.1016/S1386-6532(01)00205-0
  51. Zong JC, 1999, J VIROL, V73, P4156
  52. Zong JC, 2007, J CLIN VIROL, V40, P1, DOI 10.1016/j.jcv.2007.06.012

Coleções
Artigos e Materiais de Revistas Científicas - IMT
Carregar mais